You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》麥格理上調三生製藥(01530.HK)目標價至13.08元 評級「跑贏大市」
阿思達克 04-09 10:54
麥格理發表研究報告,指出三生製藥(01530.HK)經歷盈利連續兩年下跌及股價大幅下滑後,預期目前已見底,今年有望恢復增長,隨著4項臨床實驗結果將在年中公布,料可吸引市場關注,將目標價由10.45元上調25%至13.08元。

該行指,公司核心產品特比澳(TPIAO)、益賽普(Yisaipu)及賽普汀(Cipterbin)政策風險已消散,近期增長有改善空間,其中貢獻近半收入的特比澳,在國家醫保藥品目錄准入談判中售價下調25%,但今年銷量上升有助抵銷影響,預期銷售額將達35億元人民幣。

考慮更高開支預期,麥格理將三生製藥2021至2022年每股盈測分別下調9%及12%,重申「跑贏大市」評級。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account